Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hillhouse Capital of Beijing Co-Leads $15 Million Round for Antiva

publication date: Jul 11, 2018

Beijing's Hillhouse Capital and Sirona Capital of Australia have co-led a $15 million Series C-1 funding for Antiva Bioscience, a South San Francisco biopharma developing topical treatments for pre-cancerous lesions caused by HPV infection. Currently, Antiva is testing its lead compound, ABI-1958, for safety and efficacy in two Phase Ib clinical trials. Antiva said Hillhouse would be helpful in forming partnerships to develop its products in China, an area of high incidence for HPV and cervical cancer. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event

Shanghai , China
March 5-6, 2019

Shanghai , China
March 26-28, 2019